Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia

Inclusion Criteria: * Sexually active with self-identified dyspareunia (pain with sexual activity), at least moderate to severe and most bothersome symptom of vulvovaginal atrophy (VVA) * Postmenopausal and meets 1 of the following: 12 months spontaneous amenorrhea, 6 months spontaneous amenorrhea with FSH (follicle stimulating hormone) \>40 mIU/mL,6 weeks postsurgical bilateral oophorectomy with confirmation by FSH \>40 mIU/mL, surgical report or ultrasound, 6 weeks postsurgical hysterectomy with ovary failure confirmed by FSH \>40 mIU/mL * Age ≥40 years; ≥35 with bilateral oophorectomy * Vaginal pH \>5.0 * Less than or equal to 5% superficial cells on vaginal wall cytologic smear * Normal clinical breast exam or negative mammogram if ≥ 40 years of age * Negative urine pregnancy test (non-hysterectomized and \<12 months amenorrhea) Exclusion Criteria: * Enrollment in Sponsor's Study PR-04409 or PR-05812 * Participation in clinical trial or use of investigational drug within 30 days prior to screening * Known hypersensitivity to estrogen and/or progestin therapy * Known or suspected premalignant or malignant disease or history steroid-dependent malignancy * Manifestation or treatment for significant cardiovascular disease (congestive heart failure, stroke or ischemic attack, myocardial infarction, coronary artery bypass, percutaneous angioplasty or \>50% angiographic narrowing of coronary artery * Thrombophlebitis or thromboembolic disorder or history of * Insulin-dependen…